Portfolio News BobcatBio

SIRPant Immunotherapeutics (now BobcatBio) Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors

By WebmasterDecember 12, 2023March 18th, 2026No Comments

SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors

Previous PostImmunome to Acquire Antibody-Related Assets and Materials from Atreca
Next PostVittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma